Pharming (PHAR) Long-Term Investments (2019 - 2026)

Pharming's Long-Term Investments history runs 7 years deep, the most recent figure standing at $1.5 million for Q1 2026.

• Quarterly Long-Term Investments rose 128.12% year-over-year to $1.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.5 million (up 128.12% YoY) and the FY2025 annual result came in at $1.9 million, up 317.17% from the prior year.
• Long-Term Investments was $1.5 million for Q1 2026 at Pharming, down from $1.9 million in the prior quarter.
• Across five years, Long-Term Investments topped out at $7.8 million in Q2 2022 and bottomed at $466000.0 in Q4 2024.
• A 5-year average of $3.4 million and a median of $1.9 million in 2025 frame the typical range for Long-Term Investments.
• Annual changes were most pronounced in 2022 — Long-Term Investments surged 98545.83% — and 2024, when it plunged 92.35%.
• Pharming's Long-Term Investments stood at $2.5 million in 2022, then surged by 143.62% to $6.1 million in 2023, then plunged by 92.35% to $466000.0 in 2024, then soared by 317.17% to $1.9 million in 2025, then fell by 21.14% to $1.5 million in 2026.
• Business Quant data shows PHAR's Long-Term Investments at $1.5 million in Q1 2026, $1.9 million in Q4 2025, and $1.0 million in Q3 2025.